suppressed myoelectrical events associated with contractions in the colon of MS patients postprandially further suggests dysfunction of the ENS. 7 CNS lesions caused by MS pathology are not necessary for altered GI motility because motor, secretory, and vasodilatory functions of the gut are regulated by the ENS independent of CNS involvement. 8, 9 The ENS lacks myelin, but enteric glia share transcriptional similarities with astrocytes and oligodendrocytes, including expression of glial fibrillary acidic protein (GFAP), 10 proteolipid protein 1 (PLP1), and myelin basic protein (MBP). 11 Importantly, disruption within any population of ENS cells, including neurons, 12 glia, 13 and interstitial cells of Cajal (ICC), 14 can result in altered GI motility. Enteric neural dysfunction contributes to a variety of disorders, including autoimmune diseases such as paraneoplastic syndrome, 15 Chagas disease, 16 diabetes, 17 and achalasia. 18 Over 20 self-antigens have been identified in MS, and many of these CNS targets are also found in the ENS, including the myelin proteins, PLP1 and MBP, and neurofilaments. 11, [19] [20] [21] [22] One study reported that 28% of MS patients have at least 1 antibody that targeted common GI mucosal antigens. 23 Recently, Wunsch and colleagues reported a loss of integrity within the ENS and slower GI transit in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS that favors B lymphocyte involvement. 24 The aim of our investigation was to validate EAE as a model for GI 
| ME THODS

| Animals
Male C57BL/6J (B6), SJL/J (SJL), and B6.129S2-Ighm tm1Cgn /J (muMT) mice were purchased from The Jackson Laboratory, Bar Harbor, ME, and SJL/JCrHsd mice were purchased from Envigo, South
Easton, MA. Mice were housed in a temperature controlled room with 12 hour light:dark cycle, with food and water ad libitum. The
University of Vermont Institutional Animal Care and Use Committee approved all animal experimental protocols.
| Mouse spinal cord homogenate preparation
Spinal cords of 30 euthanized retired SJL female breeders were extracted by insufflation, mixed with an equal volume of phosphatebuffered saline (PBS), and homogenized in a tissue grinder. They were then filtered through a 70 μm strainer, dialyzed against distilled water, and lyophilized. The lyophilized homogenate was then suspended in PBS at a concentration of 50 mg/mL and stored at −80°C. Beginning 10 days postimmunization, mice were weighed and scored daily using a previously described system. 27,28 EAE scoring was recorded as follows: 0) no symptoms, 1) tail paralysis, 2) tail paralysis and mild-moderate hind limb weakness, 3) tail paralysis and hind limb paralysis, 4) a score of 3 with urinary incontinence, and 5) moribund or death. If level 3 was reached, food pellets and Napa
| EAE induction
Nectar were placed at the bottom of the cage to facilitate nutrient and fluid intake. Mice that maintained a level 4 for 2 days, or those that reached a level 5, were euthanized and recorded as a level 5 for the remainder of the experiment duration.
| Assays of GI motility
For mice immunized with MOG or PLP peptides, motility studies were conducted at 28 days following induction, when symptoms
Key Points
• The etiology of constipation in multiple sclerosis (MS) is poorly understood. Here, we study the enteric nervous system (ENS) and autoantibody involvement in gastrointestinal (GI) dysmotility in a mouse model of MS.
• Mice induced with EAE develop GI dysmotility that is associated with ENS dysfunction and circulating autoantibodies.
• These data suggest that constipation in MS is antibodymediated and independent of spinal cord demyelination, which may support the use of B cell-focused therapies in MS patients who exhibit severe GI involvement.
had typically peaked and recovered slightly. In mice immunized with MSCH, motility analyses were initiated at the onset of somatic motor symptoms. On separate days, mice sequentially underwent assays of fecal water content, colonic transit (MSCH mice only), whole GI transit, and upper GI transit.
| Whole GI transit
Animals received a 300 μL oral gavage of 6% carmine red (Sigma Aldrich) and 0.5% methylcellulose (Sigma Aldrich) in tap water. They were placed in individual cages with no bedding, but were allowed food and water ad libitum. Fecal pellets were monitored, and whole GI transit was determined as the time until carmine red was observed in feces.
| Fecal output
Mice were placed in individual cages for 1 h. Feces was collected and weighed immediately. The pellets were dried for 24 hours at 50°C
and re-weighed to determine the water content.
| Colonic transit
Mice were lightly anesthetized with isoflurane, and a 2.3 mm bead was inserted 20 mm into the distal colon using a blunt gavage needle. Colonic transit was measured as the time from wake until bead expulsion.
| Upper GI transit
Mice were fasted without bedding for 12 hours, and water for 
| Spatiotemporal mapping
Colons were removed and pinned in an organ bath containing 
| Mouse immunohistochemistry
Longitudinal muscle and myenteric plexus (LMMP) preparations were dissected and stained for either HuD, GFAP, or S100β (1:100 rabbit anti-HuD IgG, Santa Cruz Biotechnology, 1:500 rabbit anti-GFAP, EnCor Biotechnology, or 1:1000 rabbit anti-S100β, Abcam) with a Cy3 conjugated goat anti-rabbit IgG secondary antibody 
| Human serum collection
Serum samples were collected from 40 MS patients, including those with and without constipation; and 20 age-and sex-matched nonconstipated controls. The Rome IV criteria were used to identify constipated MS patients. All protocols involving human blood collection were approved by the UVM institutional review board.
| Immunohistochemistry with EAE mouse and human serum samples
Guinea pig ileum was pinned flat, fixed in 2% paraformaldehyde and 0.2% picric acid for 24 h, and dissected to expose LMMP. Human or mouse serum was diluted to 1:200 in 1X PBS with 4% goat serum and 0.5% Triton-× 100 (Sigma Aldrich) and incubated with LMMP preparations overnight, followed by incubation with the secondary antibody
(1:150, goat anti-human or goat anti-mouse Cy3, Jackson Immuno).
| Statistics
Statistics were calculated using GraphPad Prism version 7.00 for Mac (GraphPad Software, La Jolla California USA, www.graphpad. Significance is considered as *P < .05, **P < .01, ***P < .001, and ****P < .0001.
| RE SULTS
| EAE mice exhibit features of constipation in vivo
Whole gastrointestinal transit time following oral gavage of carmine red Fecal water content was calculated as another measure of constipation. Fecal pellets from EAE mice were drier than those of control mice F I G U R E 1 Whole GI transit time is measured as the time in minutes it takes for carmine red dye administered via oral gavage to be passed in the fecal pellets of mice. Transit time is significantly slower in EAE mice induced under the B6 + MOG, SJL + PLP, and SJL + MSCH induction protocols. There was no significant difference, but a trend toward slower transit time, in the B6 + MSCH protocol.
(A, control n = 7, EAE n = 9, *P < .05; B, control n = 8, EAE n = 14, n.s.; C, control n = 8, EAE n = 7, *P < .05; D, control n = 8, EAE n = 8, *P < .05 Data represented as mean ± SEM and analyzed by 1-tailed Welch's t test F I G U R E 2 Fecal water content is lower in EAE mice compared to controls. Graphs show the percentage of water in fecal pellets collected from EAE and control mice over 1 h. (A, control n = 7, EAE n = 9, *P < .05; B, control n = 8, EAE n = 14, **P < .01; C, control n = 10, EAE n = 10, **P < .01; D, control n = 5, EAE n = 6, ****P < .0001). Data represented as mean ± SEM and analyzed by 1-tailed Welch's t test in every induction method, including B6 mice induced with MOG or MSCH, and SJL mice induced with PLP or MSCH (Figure 2A-D) .
To measure colonic propulsive motility, we calculated the time until expulsion of a small glass bead inserted 20 mm into the distal colon. Expulsion time was significantly longer in EAE mice compared to controls when tested in B6 mice and SJL mice induced with MSCH ( Figure 3 ).
Gastric emptying and small intestinal transit were measured following oral gavage of rhodamine-B dextran. Gastric emptying was accelerated in EAE mice ( Figure 4A-D) . There were no differences in small intestinal transit as measured by leading edge or geometric center in EAE mice ( Figure S1 ).
Taken together, these results from in vivo assays demonstrate that EAE mice exhibit alterations that are consistent with constipation, including slower whole gut transit, drier feces, and slower colonic motility. Furthermore, as gastric emptying was accelerated and small intestinal motility is unchanged, the data suggest that the decreased motility in the EAE mice is primarily due to altered colonic function.
| B cell-deficient EAE mice do not develop altered colonic motility
To investigate whether circulating autoantibodies contribute to altered colonic motility in EAE, experiments were conducted with B cell-deficient (muMT) mice. Colonic propulsive motility was used as an outcome measure because of the robust change elicited by EAE in this assay. Time to bead expulsion was measured in WT and muMT EAE mice with and without EAE, as well as CFA/ PTX control muMT mice. A 2-way ANOVA, taking into consideration treatment and genotype, showed a statistically significant interaction between treatment and genotype (P < .05), suggesting that EAE affects colonic motility differently in B cell-deficient mice than in wild type mice ( Figure 5A ). Consistent with the data described above, colonic propulsive motility was significantly slower in WT EAE as compared to WT control mice, whereas in muMT EAE mice, propulsive motility was not significantly different between muMT with EAE mice vs their controls. There was also no significant difference in somatic motor scores between WT EAE mice and muMT EAE mice, suggesting that the different responses of GI motility between these strains are independent of somatic symptoms and instead are related to the B-cell status of these animals ( Figure 5B ). There was a significant relationship between the cumulative disease score and colonic motility in WT mice ( Figure 5C ), but not between cumulative disease score (CDS) and colonic motility in muMT mice ( Figure 5D ). Taken together, these findings suggest that B cell-generated autoantibodies likely contribute to the slower colonic motility in EAE.
| EAE mice have altered colonic contractility ex vivo
To test whether altered colonic motility involves alterations within the colon itself, motility was investigated ex vivo in isolated segments of mouse colon. Spatiotemporal analysis of spontaneous activity was used to measure the ex vivo intervals between both
CMMCs and slow waves. SJL + MSCH and B6 + MSCH EAE mice demonstrated significantly altered patterns of CMMCs and slow wave motility compared to control mice ( Figure 6 ). In both instances, there was a shift in intervals toward longer periods of quiescence in EAE mice.
| EAE mice do not exhibit neuronal loss, but have reduced GFAP expression in glia in the ENS
To determine whether decreased colonic motility in EAE is associated with a loss of myenteric neurons, we used immunoreactivity for the pan-neuronal marker, HuD, to quantify neurons in EAE SJL + MSCH
colons. There was no difference in neuron number, ganglion size, or neuronal packing density within ganglia of EAE and control mice ( Figure S2 ). We used confocal microscopy to evaluate HuD, S100β, and GFAP distribution. There was no significant difference between the area of HuD or S100β expression ( Figure 7A-B) , but a significant decrease in the area of GFAP expression within EAE ganglia ( Figure 7C ).
| MS and EAE serum targets include neurons and glia of the ENS
As described previously, 18 guinea pig LMMP preparations were used to test whether circulating antibodies bind to proteins in the enteric nervous system. In most human samples from both the MS and control groups, the myenteric plexus exhibited more immunoreactivity than the background smooth muscle, but immunostaining with MS serum samples often resulted in specific cell types being labeled. The cellular F I G U R E 3 Colonic motility was measured as the time in minutes until expulsion of a glass bead that was inserted 2.0 cm into the distal colon. Colonic motility is significantly slower in EAE mice compared to controls. (A), control n = 8, EAE n = 6, P < .01; B), control n = 9, EAE n = 10, P < .05). Data represented as mean ± SEM and analyzed by 1-tailed Welch's t test targets of human serum from MS patients included both enteric glia, that co-localized with S100β antibodies (Figure 8A ), and enteric neurons, that co-localized with HuD antibodies ( Figure 8B ). In some cases, serum antibodies appeared to target both neurons and glia, and also included nuclear staining (data not shown). No apparent differences were observed between constipated and non-constipated MS patients. , control n = 7, EAE n = 8, *P < .05; (B), control n = 7, EAE n = 9, *P < .05; (C), control n = 6, EAE n = 5, ***P < .01; (D), control n = 14, EAE n = 12, **P < .01) Data represented as mean ± SEM and analyzed by 1-tailed Welch's t test FIGURE 5 Colonic motility was assessed by the bead expulsion assay in wild type B6 mice and muMT mice. (A), The significance of the observed differences in colonic motility was determined by 2-way ANOVA followed by Tukey's multiple comparison test. A significant interaction (P < .05) between genotype and immunization was detected. The results of the post hoc analysis demonstrated that colonic motility was significantly slower in WT EAE mice compared to WT controls (P < .01), whereas in the muMT mice, no difference was detected between control and EAE mice. (WT control n = 16, WT EAE n = 22, muMT control n = 26, muMT EAE n = 20). (B), There was no significant difference in the somatic motor scores in WT EAE mice vs muMT EAE mice, suggesting that the effect of EAE on colonic motility is independent of somatic motor scores (WT EAE n = 22, muMT EAE n = 20, n. 
| D ISCUSS I ON
This study was designed to investigate whether constipation is a feature of the EAE model of MS, and to determine whether it is associated with functional and structural changes in the ENS.
We also tested whether antibodies play a role in GI dysmotility in EAE. Our findings demonstrate that EAE mice develop aberrant GI motility both in vivo and ex vivo, as well as decreased GFAP distribution within myenteric ganglia. These data suggest that GI dysmotility in EAE is associated with functional and structural changes at the level of the ENS. Both MS and EAE serum samples exhibited heterogeneous patterns of immune staining, with targeted structures including neurons, glia, or a combination of both cell types.
When induced with EAE, B cell-deficient muMT mice did not exhibit robust colonic dysmotility, further supporting antibodies as one pathogenic factor contributing to constipation in MS.
| Colonic motility in MS
Constipation and fecal incontinence are widely reported in MS, but few studies have investigated the etiology of these symptoms.
Our data demonstrate that EAE mice have slower whole GI transit, slower colonic motility, and decreased fecal water content compared to control mice. This is consistent with Wunsch and colleagues' recent finding of slower GI transit in a B cell-mediated model of EAE mice. 24 Our findings detailed motility changes at different sites along the GI tract. Furthermore, our data are consistent with a clinical report of slow transit constipation in MS patients. 6 There is some evidence that GI involvement in MS is related to spinal cord pathology because it is sometimes associated with both urinary bladder dysfunction and clinical motor symptoms as measured by the expanded disease disability scale (EDSS).
2,29
Some MS patients present with patterns of constipation inconsistent with pelvic floor dysfunction, a primary mechanism of constipation in spinal cord disease. In order to study these functions independently of both the pelvic floor and innervation derived from the spinal cord, we used ex vivo spatiotemporal analysis to measure CMMC and slow wave patterns of motility that are generated autonomously by ENS and ICC networks located within the gut wall.
CMMCs are one factor that initiate propulsive motility and require cooperation of inhibitory and excitatory motor neurons. 30 In contrast, slow waves are generated by ICC and reflect the coordinated pacemaker activity of these cells. 30 In the present study, we detected a longer interval between both CMMC and slow wave patterns of motility in EAE compared to control mice, demonstrating longer periods of colonic quiescence in EAE.
Because the colons in our preparation were studied in isolation ex vivo, the differences in motility observed in the EAE colons are independent of extrinsic spinal cord innervation and pelvic floor
The interval between slow wave contractions and CMMCs was measured between SJL and B6 mice induced by MSCH EAE compared to control mice of either background. Graphs demonstrate the cumulative frequency distribution of each interval duration. A) SJL and B) B6 EAE mice have an altered distribution of slow wave intervals compared to controls (P < .0001). C) SJL and D) B6 EAE mice have an altered distribution of CMMC intervals compared to control mice (P < .0001). Significance was measured using the KolmogorovSmirnov test. (B6 control n = 5, B6 EAE n = 8, SJL control n = 5, SJL EAE n = 4) dysfunction. Our findings suggest that EAE, and possibly MS, is associated with altered function at the level of the intrinsic neuromuscular circuitry of the gut.
Others have reported altered intestinal neuromuscular activity in both EAE and MS, including decreased circular smooth muscle contraction in the ileum of EAE mice. 24 Clinically, MS patients have reduced amplitude and altered frequency of colonic myoelectrical spike potentials during interdigestive and postprandial states. 7 Consistent with other literature, our data suggest that constipation in MS and EAE involves dysfunction within ENS neuromuscular circuitry.
It should be noted that, in addition to decelerated colonic transit,
another factor that could contribute to the drier feces reported in the current study is decreased secretion involving changes in submucosal plexus secretory reflexes. This possibility will be explored in future studies.
| Gastric and small intestinal motility in MS
Alterations in gastric emptying are reported in MS. Approximately 50% of patients experience gastroparesis, whereas 20% experience faster gastric emptying than control subjects. 31 Our data demonstrated that EAE mice had faster gastric emptying compared to controls. This discrepancy could be related to small clinical sample sizes, and the overall shortage of GI motility studies in MS patients.
F I G U R E 7
The area of cells in the ENS was calculated in SJL mice immunized with MSCH EAE or control mice. Three different cell markers were used. (A), There was no difference in the percentage of pixels per ganglion that expressed neuron HuD, (control n = 5, EAE n = 5, n.s.) B) There was no difference in the percentage of pixels per ganglion that expressed the glial protein S100β, (control n = 5, EAE n = 5, n.s.) C) There was a significant reduction in the distribution of GFAP within ENS ganglia of EAE mice compared to control mice (control n = 5, EAE n = 5, P < .012). Data represented as mean ± SEM and analyzed by 2-tailed Welch's t test. Five ganglia were imaged per animal.
Representative images demonstrate the distribution of HuD, S100β and GFAP in control mice (D, E, F) and EAE mice (G, H, I), respectively Alternately, our finding of increased gastric emptying could represent one way in which the EAE model does not directly replicate clinical features.
Our data showed no changes in small intestinal motility, in contrast to a recent report of altered smooth muscle contraction in the ileum of a B cell-mediated EAE model. 
| No neuronal or glial loss was detected in the EAE mice, but GFAP expression was reduced in colonic myenteric ganglia
In the current study, no differences were detected in the number or density of neurons in EAE vs control mice, and no differences were detected in the area of the myenteric plexus that exhibited immunoreactivity for S100β, which is thought to be expressed by all enteric glial cells. 11 We quantified the area of GFAP expression, which is expressed by about 60% of myenteric ganglionic glial cells, 11 and detected a decrease in EAE. Conversely, Wunsch and colleagues report increased GFAP expression in small intestinal myenteric ganglia in the model of EAE that they studied.
24
These discrepant findings could be related to the different models of EAE induction, or could represent differential effects of GFAP expression throughout GI regions, which has been reported in Crohn's disease. 32 Our data could represent a phenotypic shift of glial cells between structural and functional subpopulations.
Although our studies do not demonstrate overt loss of glia, or decrease in glial numbers, both clinical 33 and experimental 13 studies report an association between enteric glial integrity and GI motility.
The changes in colonic motility, combined with absence of neuronal loss, suggest that disrupted motor function in EAE could involve changes in the physiological properties of myenteric neurons, as has been demonstrated in experimental colitis. 12 However, it is also possible that changes in glial structure and function could play a contributing role. The disruption of GFAP-expressing enteric glia has been reported in other models to induce phenotypic changes in neurons without changing neuron numbers, and is associated with altered GI motility. 
| Antibodies in MS
Autoimmune gastrointestinal dysmotility (AGID) is a clinical phenomenon that occurs when autoimmune processes, especially antibodies, target the GI tract idiopathically or secondary to another autoimmune disease. For example, in paraneoplastic syndrome, antibodies against Hu, the type 1 antineuronal nuclear antibody (ANNA-1), elicit structural and functional changes in the ENS, resulting in constipation. 35, 36 Our data demonstrate that both MS and EAE sera bind to neurons and glia in guinea pig myenteric ganglia.
Furthermore, our motility analysis in muMT mice supports a pathogenic role of antibodies in constipation associated with MS.
Over 20 CNS autoantibodies have been identified in MS 22 and several of their antigens, including proteolipid protein 1 (PLP1) are also widely expressed in the ENS. 11 A recent investigation demonstrated that many patients with autoimmune or idiopathic GI dysfunction present with increased serum antibody levels that exhibit immunoreactivity against both CNS and ENS neurons and glia and stimulated enteric secretion, with no effect on motility, when 37 In one study of GI antibodies in MS patients, 28%
of patients were found to have at least 1 antibody against mucosal antigens, suggesting the possibility of further enteric targets of the disease. 23 Together with our findings, these data suggest that MS could represent an additional autoimmune disease in which autoantibodies contribute to constipation.
The results from our studies of colonic motility in B celldeficient mice and immunoreactivity with human MS and mouse EAE serum samples strongly support a role of autoantibodies in MS-related constipation. Both MS and EAE serum samples were found to contain antibodies that target ENS structures in the Wunsch et al study as well. 24 Here, we demonstrate that B celldeficient EAE mice do not develop colonic dysmotility, and that in the absence of B cells, there is no relationship between somatic motor scores and colonic motility. This is interesting because, as is the case with MS, the somatic pathogenesis of the EAE models used in the current study is primarily T cell-mediated, with B cells contributing indirectly. 38 Thus, the findings of the current study support and expand upon the previous report 24 of GI motility changes in a B cell-mediated model of EAE.
Other factors, in addition to autoantibodies, could play a contributing role in the motility changes reported here. It is possible that the decreased rate of colonic motility that was observed represents a sickness response, constituting fever, malaise, and anorexia, that is not disease specific. Furthermore, it is possible that circulating pro-inflammatory agents such as cytokines associated with the EAE inflammatory response could affect neuronal and/or glial function, and it is also possible that immune cells could directly influence the neurons and glia. For example, Wunsch and colleagues report infiltrating B lymphocytes, T lymphocytes, and macrophages in the myenteric ganglia of the EAE model that they used. 24 Future studies will be designed to test the influence of these factors.
| Concluding remarks
In this study, we have conducted a broad analysis of GI motility in the EAE mouse model to improve our understanding of dysmotility in patients with MS. Our models are consistent with many features supporting clinical constipation, and our data suggest that EAE is associated with functional and structural changes of the ENS. Our data importantly demonstrate that the observed dysmotility represent alterations in the ENS itself. Collectively, these studies advance our knowledge of enteric pathophysiology associated with MS that could lead to improved treatment of constipation in these patients.
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